FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3034283341> ?p ?o ?g. }

• W3034283341 endingPage "105007" @default.
• W3034283341 startingPage "105007" @default.
• W3034283341 abstract "Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) were first-line treatments for NSCLC patients with EGFR-mutations. However, about 30 % of responders relapsed within six months because of acquired resistance. In this study, we used Connectivity Map (CMap) to discover a drug capable of reversing acquired EGFR-TKIs resistance. To investigate Lymecycline’s ability to reverse acquired EGFR-TKIs resistance, two Icotinib resistant cell lines were constructed. Lymecycline’s ability to suppress the proliferation of Icotinib resistant cells in vitro and in vivo was then evaluated. Molecular targets were predicted using network pharmacology and used to identify the molecular mechanism. Growth factor receptor-bound protein 2 (GRB2) is an EGFR-binding adaptor protein essential for EGFR phosphorylation and regulation of AKT/ERK/STAT3 signaling pathways. Lymecycline targeted GRB2 and inhibited the resistance of the cell cycle to EGFR-TKI, arresting disease progression and inducing apoptosis in cancer cells. Combined Lymecycline and Icotinib treatment produced a synergistic effect and induced apoptosis in HCC827R5 and PC9R10 cells. Cell proliferation in resistant cancer cells was significantly inhibited by the combined Lymecycline and Icotinib treatment in mouse models. Lymecycline inhibited the resistance of the cell cycle to EGFR-TKI and induced apoptosis in NSCLC by inhibiting EGFR phosphorylation and GRB2-mediated AKT/ERK/STAT3 signaling pathways. This provided strong support that Lymecycline when combined with EGFR targeting drugs, enhanced the efficacy of treatments for drug-resistant NSCLC." @default.
• W3034283341 created "2020-06-19" @default.
• W3034283341 creator A5006455181 @default.
• W3034283341 creator A5009866828 @default.
• W3034283341 creator A5012991197 @default.
• W3034283341 creator A5023666312 @default.
• W3034283341 creator A5032600833 @default.
• W3034283341 creator A5041651426 @default.
• W3034283341 creator A5059148873 @default.
• W3034283341 creator A5073846027 @default.
• W3034283341 creator A5081605026 @default.
• W3034283341 creator A5082117229 @default.
• W3034283341 creator A5087002756 @default.
• W3034283341 creator A5088595151 @default.
• W3034283341 creator A5089909886 @default.
• W3034283341 creator A5091458494 @default.
• W3034283341 date "2020-09-01" @default.
• W3034283341 modified "2023-10-18" @default.
• W3034283341 title "Lymecycline reverses acquired EGFR-TKI resistance in non–small-cell lung cancer by targeting GRB2" @default.
• W3034283341 cites W1965659086 @default.
• W3034283341 cites W1983933325 @default.
• W3034283341 cites W2017119868 @default.
• W3034283341 cites W2023811787 @default.
• W3034283341 cites W2025477394 @default.
• W3034283341 cites W2033591223 @default.
• W3034283341 cites W2035618305 @default.
• W3034283341 cites W2069429410 @default.
• W3034283341 cites W2083802748 @default.
• W3034283341 cites W2087976775 @default.
• W3034283341 cites W2099326052 @default.
• W3034283341 cites W2100143259 @default.
• W3034283341 cites W2114004559 @default.
• W3034283341 cites W2121604817 @default.
• W3034283341 cites W2127791026 @default.
• W3034283341 cites W2132157071 @default.
• W3034283341 cites W2136617988 @default.
• W3034283341 cites W2279201083 @default.
• W3034283341 cites W2343879804 @default.
• W3034283341 cites W2406874125 @default.
• W3034283341 cites W2415173052 @default.
• W3034283341 cites W2508069933 @default.
• W3034283341 cites W2612467560 @default.
• W3034283341 cites W2624737489 @default.
• W3034283341 cites W2646098581 @default.
• W3034283341 cites W2763105571 @default.
• W3034283341 cites W2765099528 @default.
• W3034283341 cites W2767848966 @default.
• W3034283341 cites W2768852352 @default.
• W3034283341 cites W2770828094 @default.
• W3034283341 cites W2791456383 @default.
• W3034283341 cites W2795708883 @default.
• W3034283341 cites W2806722702 @default.
• W3034283341 cites W2808680713 @default.
• W3034283341 cites W2809029138 @default.
• W3034283341 cites W2810609739 @default.
• W3034283341 cites W2885231453 @default.
• W3034283341 cites W2896548682 @default.
• W3034283341 cites W2907178432 @default.
• W3034283341 cites W2911423692 @default.
• W3034283341 cites W2922490216 @default.
• W3034283341 cites W2941280883 @default.
• W3034283341 cites W2946412700 @default.
• W3034283341 cites W2947090615 @default.
• W3034283341 cites W2950062269 @default.
• W3034283341 cites W2951601616 @default.
• W3034283341 cites W2955249862 @default.
• W3034283341 cites W2957556946 @default.
• W3034283341 cites W2962067817 @default.
• W3034283341 cites W2991443190 @default.
• W3034283341 cites W3005976568 @default.
• W3034283341 cites W3024031448 @default.
• W3034283341 doi "https://doi.org/10.1016/j.phrs.2020.105007" @default.
• W3034283341 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32561477" @default.
• W3034283341 hasPublicationYear "2020" @default.
• W3034283341 type Work @default.
• W3034283341 sameAs 3034283341 @default.
• W3034283341 citedByCount "13" @default.
• W3034283341 countsByYear W30342833412020 @default.
• W3034283341 countsByYear W30342833412021 @default.
• W3034283341 countsByYear W30342833412022 @default.
• W3034283341 countsByYear W30342833412023 @default.
• W3034283341 crossrefType "journal-article" @default.
• W3034283341 hasAuthorship W3034283341A5006455181 @default.
• W3034283341 hasAuthorship W3034283341A5009866828 @default.
• W3034283341 hasAuthorship W3034283341A5012991197 @default.
• W3034283341 hasAuthorship W3034283341A5023666312 @default.
• W3034283341 hasAuthorship W3034283341A5032600833 @default.
• W3034283341 hasAuthorship W3034283341A5041651426 @default.
• W3034283341 hasAuthorship W3034283341A5059148873 @default.
• W3034283341 hasAuthorship W3034283341A5073846027 @default.
• W3034283341 hasAuthorship W3034283341A5081605026 @default.
• W3034283341 hasAuthorship W3034283341A5082117229 @default.
• W3034283341 hasAuthorship W3034283341A5087002756 @default.
• W3034283341 hasAuthorship W3034283341A5088595151 @default.
• W3034283341 hasAuthorship W3034283341A5089909886 @default.
• W3034283341 hasAuthorship W3034283341A5091458494 @default.
• W3034283341 hasBestOaLocation W30342833411 @default.
• W3034283341 hasConcept C121608353 @default.

• next